Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

957 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3.
Molina JM, Cohen C, Katlama C, Grinsztejn B, Timerman A, Pedro Rde J, Vangeneugden T, Miralles D, Meyer SD, Parys W, Lefebvre E; TMC114-C208 Study Group; TMC114-C215 Study Group. Molina JM, et al. J Acquir Immune Defic Syndr. 2007 Sep 1;46(1):24-31. doi: 10.1097/QAI.0b013e3181359cfb. J Acquir Immune Defic Syndr. 2007. PMID: 17621237 Clinical Trial.
Recovery of fat following a switch to nucleoside reverse transcriptase inhibitor-sparing therapy in patients with lipoatrophy: results from the 96-week randomized ANRS 108 NoNuke Trial.
Valantin MA, Lanoy E, Bentata M, Kalmykova O, Boutekadjirt A, Allavena C, Rozenbaum W, Peytavin G, Amellal B, Calvez V, Costagliola D, Katlama C; NoNuke ANRS 108 Study Team. Valantin MA, et al. HIV Med. 2008 Oct;9(8):625-35. doi: 10.1111/j.1468-1293.2008.00606.x. Epub 2008 Jul 8. HIV Med. 2008. PMID: 18624724 Free article. Clinical Trial.
Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial.
Duvivier C, Ghosn J, Assoumou L, Soulié C, Peytavin G, Calvez V, Génin MA, Molina JM, Bouchaud O, Katlama C, Costagliola D; ANRS 121 study group. Duvivier C, et al. Among authors: molina jm. J Antimicrob Chemother. 2008 Oct;62(4):797-808. doi: 10.1093/jac/dkn278. Epub 2008 Jul 18. J Antimicrob Chemother. 2008. PMID: 18641035 Clinical Trial.
Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials.
Marcelin AG, Flandre P, Molina JM, Katlama C, Yeni P, Raffi F, Antoun Z, Ait-Khaled M, Calvez V. Marcelin AG, et al. Among authors: molina jm. Antimicrob Agents Chemother. 2008 Dec;52(12):4251-7. doi: 10.1128/AAC.00514-08. Epub 2008 Oct 13. Antimicrob Agents Chemother. 2008. PMID: 18852278 Free PMC article. Clinical Trial.
957 results